1. Home
  2. SYBX vs TRAW Comparison

SYBX vs TRAW Comparison

Compare SYBX & TRAW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SYBX
  • TRAW
  • Stock Information
  • Founded
  • SYBX N/A
  • TRAW 1998
  • Country
  • SYBX United States
  • TRAW United States
  • Employees
  • SYBX N/A
  • TRAW N/A
  • Industry
  • SYBX Biotechnology: Pharmaceutical Preparations
  • TRAW
  • Sector
  • SYBX Health Care
  • TRAW
  • Exchange
  • SYBX Nasdaq
  • TRAW NYSE
  • Market Cap
  • SYBX 11.8M
  • TRAW 10.1M
  • IPO Year
  • SYBX N/A
  • TRAW 2013
  • Fundamental
  • Price
  • SYBX $1.16
  • TRAW $1.54
  • Analyst Decision
  • SYBX
  • TRAW
  • Analyst Count
  • SYBX 0
  • TRAW 0
  • Target Price
  • SYBX N/A
  • TRAW N/A
  • AVG Volume (30 Days)
  • SYBX 13.5K
  • TRAW 55.1K
  • Earning Date
  • SYBX 05-13-2025
  • TRAW 05-14-2025
  • Dividend Yield
  • SYBX N/A
  • TRAW N/A
  • EPS Growth
  • SYBX N/A
  • TRAW N/A
  • EPS
  • SYBX N/A
  • TRAW N/A
  • Revenue
  • SYBX $8,000.00
  • TRAW $226,000.00
  • Revenue This Year
  • SYBX N/A
  • TRAW $3.81
  • Revenue Next Year
  • SYBX N/A
  • TRAW $30.43
  • P/E Ratio
  • SYBX N/A
  • TRAW N/A
  • Revenue Growth
  • SYBX N/A
  • TRAW N/A
  • 52 Week Low
  • SYBX $0.90
  • TRAW $1.52
  • 52 Week High
  • SYBX $1.96
  • TRAW $19.44
  • Technical
  • Relative Strength Index (RSI)
  • SYBX 50.18
  • TRAW 26.40
  • Support Level
  • SYBX $1.00
  • TRAW $1.67
  • Resistance Level
  • SYBX $1.10
  • TRAW $2.63
  • Average True Range (ATR)
  • SYBX 0.10
  • TRAW 0.30
  • MACD
  • SYBX 0.01
  • TRAW 0.03
  • Stochastic Oscillator
  • SYBX 84.64
  • TRAW 0.84

About SYBX Synlogic Inc.

Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.

About TRAW TRAWS PHARMA INC

Traws Pharma Inc is a biopharmaceutical company focused on developing antivirals for influenza, COVID and other respiratory infections and narazaciclib.

Share on Social Networks: